Fatty liver disease

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Retrieved on: 
Thursday, February 8, 2024
Principal, ALT, Liver failure, Fatty liver disease, Cirrhosis, Hepatotoxicity, Nausea, GGT, Death, Therapy, Biomarker, Patient, Breakthrough therapy, Safety, Incidence, FDA, NAFLD, Lipoprotein, Priority review, Diarrhea, NAS, Woman, University of Oxford, Disease, Drug development, Fibrosis, Biopsy, Risk, Week, Heart rate, PDUFA, CAP, NASH, Medicine, Liver cancer, Liver, Pharmaceutical industry

NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.

Key Points: 
  • NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally.
  • Resmetirom received Breakthrough Therapy designation from the FDA and is under review to become the first medicine approved to treat patients with NASH with liver fibrosis.
  • Approximately 50% of patients treated with resmetirom 100 mg with biopsies at Week 52 showed either NASH resolution or fibrosis improvement.
  • More than 80% of patients with biopsies at Week 52 had either fibrosis reversal or no progression of fibrosis.

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Retrieved on: 
Wednesday, February 7, 2024
SIRT6, Fatty liver disease, Investigational New Drug, Research, Therapy, CDMO, Patient, IND, Longevity, EMA, Patent Cooperation Treaty, QMS, Medication, European Medicines Agency, Werner syndrome, NASH, GMP, PCT, Pharmaceutical industry

LONDON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.

Key Points: 
  • LONDON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.
  • Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.
  • Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.
  • Dr. Eric Leire, CEO of Genflow commented: “The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 6, 2024
Therapy, NASH, Fatty liver disease, Employment, Certification, Pharmaceutical industry

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The equity awards were granted as inducement material to the employees’ acceptance of employment with the company.
  • All time-based restricted stock units granted vest in a 25% increment on each of the first through fourth anniversaries of the grant date.
  • The vesting of all awards described above shall be subject to each such employee’s continued employment as of the vesting date.

Nordic Bioscience to make its precision medicine biomarker PRO-C3 available in China for research use only (RUO) in the first quarter of 2024.

Retrieved on: 
Tuesday, February 6, 2024
Support, Fatty liver disease, Conditional sentence, Research, Biomarker, Patient, Labcorp, FDA, Idiopathic pulmonary fibrosis, IPF, Drug development, Letter, RUO, Neoplasm, MASH, ECM, NASH, Fine chemical

All testing outside China continues to be offered exclusively at Nordic Bioscience's laboratories in Herlev, Denmark.

Key Points: 
  • All testing outside China continues to be offered exclusively at Nordic Bioscience's laboratories in Herlev, Denmark.
  • The availability of PRO-C3 as RUO in China will allow drug developers and scientists in China pre-IVD access to PRO-C3, which will be offered via LabCorp in Shanghai.
  • "This collaboration will allow faster and broader access to Nordic's precision medicine enabling biomarker PRO-C3.
  • The license agreement between Nordic Bioscience and Roche will put multiple Nordic Bioscience biomarkers on the fully automated cobas® e platform from Roche over the coming years.

Nordic Bioscience to make its precision medicine biomarker PRO-C3 available in China for research use only (RUO) in the first quarter of 2024.

Retrieved on: 
Tuesday, February 6, 2024
Support, Fatty liver disease, Conditional sentence, Research, Biomarker, Patient, Labcorp, FDA, Idiopathic pulmonary fibrosis, IPF, Drug development, Letter, RUO, Neoplasm, MASH, ECM, NASH, Fine chemical

All testing outside China continues to be offered exclusively at Nordic Bioscience's laboratories in Herlev, Denmark.

Key Points: 
  • All testing outside China continues to be offered exclusively at Nordic Bioscience's laboratories in Herlev, Denmark.
  • The availability of PRO-C3 as RUO in China will allow drug developers and scientists in China pre-IVD access to PRO-C3, which will be offered via LabCorp in Shanghai.
  • "This collaboration will allow faster and broader access to Nordic's precision medicine enabling biomarker PRO-C3.
  • The license agreement between Nordic Bioscience and Roche will put multiple Nordic Bioscience biomarkers on the fully automated cobas® e platform from Roche over the coming years.

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Retrieved on: 
Thursday, February 1, 2024
SIRT6, Fatty liver disease, Investigational New Drug, Research, Therapy, CDMO, Patient, IND, Longevity, EMA, Patent Cooperation Treaty, QMS, Medication, European Medicines Agency, Werner syndrome, NASH, GMP, PCT, Pharmaceutical industry

LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024.

Key Points: 
  • The full year-end review can be viewed on Genflow’s website: https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/.
  • Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.
  • Began trading on the OTCQB Venture Market in the US under the ticker GENFF, aligned to its US-focused strategy.
  • Dr. Eric Leire, CEO of Genflow commented: “The milestones we reached in 2023 were numerous, and I commend our team for their exceptional commitment to execution and delivery.

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Hepatocellular carcinoma, CANF, Fatty liver disease, Pancreatic cancer, Psoriasis, HCC, CEE, Inflammation, NASH, Eisai, Pharmaceutical industry

to include the pancreatic cancer indication of Can-Fite.

Key Points: 
  • to include the pancreatic cancer indication of Can-Fite.
  • Ewopharma AG exercised its right to expand the distribution agreement to include the indication of pancreatic cancer and the transaction terms of the distribution agreement are applicable to such indication.
  • In addition to Can-Fite, Ewopharma AG has distribution agreements with many leading healthcare companies including Eisai and Biogen.
  • “We are very pleased to expand the distribution agreement with Ewopharma, a leader in pharmaceutical distribution in Central Eastern Europe and Switzerland and include the pancreatic cancer indication.

The Plug Drink Unveils Enhanced 5.0 Formula, Embraces Innovation with Upgraded Taste Profile, New Certifications, and Boosted Herbal Concentration

Retrieved on: 
Thursday, February 1, 2024
Fatty liver disease, Taste, Carbon, Plug, Entrepreneurship, Mission, Formula, The Beauty of Independence

With an unwavering commitment to innovation and consumer well-being, the two-year-long project enhanced the formula's herbal concentration by three times, improving its flavor profile, and becoming more inclusive to those with dietary restrictions.

Key Points: 
  • With an unwavering commitment to innovation and consumer well-being, the two-year-long project enhanced the formula's herbal concentration by three times, improving its flavor profile, and becoming more inclusive to those with dietary restrictions.
  • The formula boasts the highest herbal concentration (10.83g), while also lowering the calories (40 to 15) and the carbs (11g to 4g).
  • Get A Taste of NEW The Plug Drink 5.0 Formula exclusively here.
  • "The Plug Drink 5.0 is not the peak of all that we have to offer," said Justin Kim, Co-Founder and COO.

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

Retrieved on: 
Monday, January 29, 2024
Senior, Engineering, Rensselaer Polytechnic Institute, Amgen, Therapy, Central Connecticut State University, Pratt & Whitney, Fibrosis, Divisional patent application, Loyola University, Human resources, Entrepreneurship, Business, Manufacturing engineering, M.B.A, GE HealthCare, University, Cancer, Organization, Fatty liver disease, Duke University, Frazier Healthcare Partners, Horizon Therapeutics, Johnson & Johnson, NASH, Officer (armed forces), BASF, Institutional Investor, Management

“I am delighted to welcome Mark, Clint and Tina to the team,” said Bill Sibold, Chief Executive Officer of Madrigal.

Key Points: 
  • “I am delighted to welcome Mark, Clint and Tina to the team,” said Bill Sibold, Chief Executive Officer of Madrigal.
  • “As we prepare for a first-to-market launch of resmetirom in NASH with significant fibrosis, we are also building a foundation for enduring leadership.
  • Prior to Kenvue, he was the Senior Vice President Human Resources, North America, Sanofi, from 2016-2022, serving as a member of the Sanofi Global HR Leadership Team.
  • Tina Ventura brings nearly 25 years of experience in global health care investor relations and communications to Madrigal.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, January 22, 2024
NASH, Fatty liver disease, Employment, Therapy, Pharmaceutical industry

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The equity awards were granted as inducement material to the employees’ acceptance of employment with the company.
  • All restricted stock units granted vest in a 25% increment on each of the first through fourth anniversaries of the grant date.
  • The vesting of all awards described above shall be subject to each such employee’s continued employment as of the vesting date.